about
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective ...
Read More
1.18
0.03
(2.61%)
248.5K
XNAS Volume
XNAS 13 Mar, 2026 5:30 PM (EDT)
Not Eligible
Expensive Valuation
Technically Bearish
MEI Pharma Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..